News archive

Ex. Subscription Rights today

May 21, 2024
Issuer: Lifecare ASA Ex. date: 21 May 2024 Type of corporate action: Preferential rights issue Other information: The shares in Lifecare ASA will from today, 21 May 2024, be traded exclusive of the right to receive subscription rights for shares in the preferential rights issue announced on 25 April 2024.
Read more

Minutes from Extraordinary General Meeting

May 16, 2024
The Extraordinary General Meeting of Lifecare ASA was convened as a hybrid meeting on 16 May 2024. All proposals on the agenda were adopted, cf. the notification of the Extraordinary General Meeting that was published on Oslo Stock Exchange on 2. May 2024. The complete minutes of the Extraordinary General Meeting are attached and will […]
Read more

Updated key information relating to the preferential rights issue

May 15, 2024
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. Reference is made to the stock exchange announcement published […]
Read more

Lifecare Q1 2024 Report – From preparations phase to pilot production

May 8, 2024
Bergen, Norway, May 5th, 2024: Today, Lifecare AS (LIFE) (the “Company”), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes Q1 financial report and operational update. Lifecare Q1 report 2024 is available here Lifecare has been delivering milestones on a continuous basis over a long period. The company has […]
Read more

Lifecare becomes majority shareholder in RemovAid

April 29, 2024
Bergen, Norway, 29 April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), have invested NOK 2 million through a private placement in RemovAid AS, a medical technology company based in Oslo, Norway, after which Lifecare holds 81.1% of the shares in RemovAid. RemovAid has developed […]
Read more

Strategic investment in RemovAid AS

April 26, 2024
Bergen, Norway, 26th April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), intend to invest NOK 2 million and become the majority shareholder in RemovAid AS, a medical technology company based in Oslo, Norway. RemovAid is an ISO 13485 certified company who specializes in the […]
Read more

Lifecare BoD propose a partially underwritten rights issue

April 26, 2024
Bergen, Norway, 26 April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), intent to invite its existing shareholders in a NOK 90 million partially underwritten rights issue. The proposed rights issue will ensure preferential subscription rights for existing shareholders, with already underwritten guarantees a minimum […]
Read more

Presentation at MARSS 2024

April 16, 2024
Lifecare’s Dr. Preeti Sharma is invited as a speaker to present a paper at International Conference on Manipulation, Automation and Robotics at Small Scales (MARSS 2024) in Delft, Netherlands. The paper “Towards Scanning Electron Microscope (SEM) automation” is accepted by the MARSS 2024 Organization Committee and assigned for an oral presentation at the conference in […]
Read more

Breakthrough: Reaching target for pilot production

April 3, 2024
Bergen, Norway, 3rd April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), has successfully reached the target for pilot production of the Sencell sensor. Reports show a breakthrough, and this will pave the way for the automated production by end of Q2 as scheduled. Reference […]
Read more

The European Patent Office issues a new Lifecare patent

March 21, 2024
Bergen, Norway, March 21st, 2024: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that the European Patent Office (EPO) has notified that they will grant for a new patent to Lifecare. Reference is made to stock exchange notification November 8th, 2023, that EPO intended […]
Read more